A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder [also known as AIR® Inhaled Insulin][AIR® is a registered trademark of Alkermes,Inc.] in patients with Type 2 diabetes who are currently being treated with once daily insulin glargine injections. The present study is intended to determine if mealtime AIR® Insulin may be superior to once-daily insulin glargine injections.

Inclusion Criteria:

• type 2 diabetes mellitus
• one or more oral antihyperglycemic medications
• once-daily insulin glargine
• HbA1c greater than or equal to 7.5 and less than or equal to 10.5%
• Non-smoker

Exclusion Criteria:

• taking a TZD dose greater than what is indicated
• more than two episodes of severe hypoglycemia during the 6 months prior
• Have had a lower respiratory infection in the 3 months prior
• systemic glucocorticoid therapy
• clinical signs or symptoms of liver disease, acute or chronic hepatitis
• history of renal transplantation
• Have an active or untreated malignancy
• Require more than 150 U/day of insulin glargine

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.